NCT02588326View on ClinicalTrials.gov

Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of Suspension-based Nasal Sprays

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 21, 2018

Primary Completion Date

July 8, 2020

Study Completion Date

April 16, 2021

Conditions
Hypersensitivity
Interventions
DRUG

Mometasone furoate drug formulation (MFF) 1

Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray.

DRUG

Mometasone furoate drug formulation (MFF) 2

Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray.

Trial Locations (1)

32610

Department of Pharmaceutics, University of Florida, Gainesville

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

Food and Drug Administration (FDA)

FED

collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Florida

OTHER

NCT02588326 - Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of Suspension-based Nasal Sprays | Biotech Hunter | Biotech Hunter